MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan
This article was originally published in PharmAsia News
TOKYO - In contrast to wide criticisms about long drug lags in Japan, the Ministry of Health, Labor and Welfare has approved Abbott's rheumatoid arthritis antibody drug Humira (adalimumab) to be distributed by Eisai in Japan, the two companies announced June 17
You may also be interested in...
TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).